Ucla Biomedical Company Profile
✉ Email this page to a colleague
What is the competitive landscape for UCLA BIOMEDICAL
UCLA BIOMEDICAL has two approved drugs.
Drugs and US Patents for Ucla Biomedical
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ucla Biomedical | FLUDEOXYGLUCOSE F18 | fludeoxyglucose f-18 | INJECTABLE;INTRAVENOUS | 203811-001 | Jun 27, 2013 | AP | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ucla Biomedical | AMMONIA N 13 | ammonia n-13 | INJECTABLE;INTRAVENOUS | 203812-001 | Jun 27, 2013 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.

